ClearCount Medical Solutions has closed its Series B funding round with the hoped-for $5 million.
ClearCount Medical has developed the SmartSponge and SmartWand systems, which use radio-frequency identification (RFID) technology and chips embedded in sponges to allow surgeons and nurses to detect and count sponges during operations.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Surgical sponges are the most frequent and dangerous “retained surgical items” (RSIs) that are mistakenly left inside patients. Research has shown that retained sponges can cause infectious complications in as few as 30 minutes. The Centers for Medicare & Medicaid Services have stopped reimbursing hospitals and physicians for such “never events.”
The latest tranche of money for the Pittsburgh, Pennsylvania, company was $3.5 million, according to a Securities and Exchange Commission filing. The funding round was supported by new and existing shareholders and led by Draper Triangle Ventures, the Pittsburgh-based partner of Draper Fisher Jurvetson, the company said in a press release.
ClearCount will use the money to “drive market penetration, and research and development of its RFID-based solutions for hospital patient safety applications,” according to the release. It also plans to support its exclusive distribution deal with Medline Industries Inc. (pdf), which the companies announced in December, CFO Dave Haffner said in May.
“Thanks to the strong backing of our investors, this past year ClearCount completed a valuable distribution deal, signed major new customers and introduced an important new product that is making surgical procedures safer every day,” said ClearCount CEO David Palmer in the release.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
ClearCount’s products also can reduce or eliminate preventable hospital costs and delays associated with RSIs, including additional surgery and infection costs, litigation, unnecessary X-rays and anesthesia, the company said.
“ClearCount’s patented RFID technology and offerings are more relevant than ever,” said Mike Stubler, managing director of Draper Triangle, in ClearCount’s release. “As improving the quality of healthcare continues to be a national focus, solutions that can also impact the efficiency and value a hospital offers its patients are sure to be adopted.”
